

Investor Briefing: Half Year FY 2026

2 March 2026

Merrill Gray, MD/CEO

Disclaimer



IMPORTANT INFORMATION

The purpose of the presentation is to provide an update of the business of AnteoTech Ltd (ASX:ADO) (AnteoTech). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by AnteoTech and should not be relied upon as an independent source of information. Please contact AnteoTech and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

FORWARD-LOOKING STATEMENTS

The presentation may contain certain “forward-looking statements”. Forward-looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “would”, “could”, “expect”, “intend”, “plan”, “aim”, “estimate”, “target”, “anticipate”, “believe”, “continue”, “objectives”, “outlook”, “guidance” or other similar words, and include statements regarding AnteoTech's intent, belief or current expectations with respect to AnteoTech's business and operations, market conditions, results of operations and financial condition, capital adequacy and risk management. These forward-looking statements should not be relied upon as a representation or warranty, express or implied, as to future matters. Prospective financial information has been based on current expectations about future events and is, however, subject to risks, uncertainties, contingencies and assumptions that could cause actual results to differ materially from the expectations described in such prospective information. AnteoTech disclaims any obligation to update any forward-looking statement to reflect events or circumstances after the date of the presentation, subject to the disclosure requirements applicable to the Group.

NOT AN OFFER OF SECURITIES

This presentation should not be relied on as a recommendation or forecast by AnteoTech. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. The information in this presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account your financial objectives, situation or needs. Investors should consult with their own legal, tax, business and/or financial advisors in connection with any investment decision.

AnteoBind™ NXT, Anteo X®, Anteo S™ and Ultranode® are trademarks of AnteoTech. The use of registered and pending trademark symbols throughout the presentation is implied.

All \$ quoted are AUD unless otherwise stated.



Agenda



- **AnteoTech FY 2026 Half Year (Interim) Report Summary**
- **Business Overview**
- **Advanced Battery Materials update**
- **Life Sciences update**
- **Moving Forward**

Half Yearly/Interim Results H1 FY 2026

- ✓ Cost base structurally reset
- ✓ Sales Pipeline expanded across LS and ABT
- ✓ Key Performance and Development milestones achieved:-
 - Ultranode® X achieved 1,020 cycles at 80% capacity retention,
 - SiMRAX (Anteo X™ containing) joint product JDA progressed,
 - Launch of a new separator product, Anteo S™, and
 - Comparative Evaluation of AnteoBind™ NXT and Tosyl-Activated Magnetic Particles in Chemiluminescent Immunoassays (CLIA) work completed.
- ✓ \$3.5 million Capital Raise completed, post period end
- ✓ Focus is on sales conversion and securing partnerships


Improved Financial position: H1 FY2025 vs H1 FY2026



Cost Reductions secured

(Comparing Feb 2026 to Feb 2025)

- ✓ Full-Time Equivalent (FTE) employee cost reduction
- ✓ Contract employee costs reduction, by 35%
- ✓ Directors' costs reduction, by ~\$114,000 p.a.
- ✓ Travel and accommodation costs for employees residing interstate reduction to nil



Revenues were impacted due to the timing of sales to the Serum Institute of India (SII) which has a five-year \$US1.8m take or pay commercial supply agreement¹. If sales to the Serum Institute of India are excluded from both periods, sales to other parties increased by 6%.

¹ See ASX Announcement 30 July 2024: "US\$1.8m AnteoBind Purchase Agreement over 5 years"

Financial Summary Half Year to 31 Dec 2025

\$,000's	H1 FY2026	H1 FY2025	
	Jul - Dec 2025	Jul - Dec 2024	Variance
Revenue			
Sales Revenue	97 #	660 ^	-85%
Other income	2,598	2,494	4%
Interest revenue	12	31	-61%
Total revenue and other income	2,707	3,185	-15%
Expenses			
Selling and distribution expenses	340	354	4%
Admin & Occupancy expenses	1,575	1,840	14%
Research expenses	1,357	1,971	31%
Depreciation and amort. expenses	555	559	1%
Share-based payments expenses	282	656	57%
Total expenses	4,110	5,380	24%
Loss before income tax expense	-1,403	-2,195	36%

Note: Above excludes non-cash items.


Cash in bank as of 31 January 2026 was \$1,560,000 inclusive of \$402,950 relating to the Capital raise, with No Debt.

= US\$185,000 was received from SII on 5 January 2026. If this sale was included in H1 FY2026 sales, the total sales would have been \$372 750 for the half year.

^ = two SII payments received


Note: One more SII payment expected for the year of around US\$180,000 taking their orders to around A\$550,000 for the year, the previous year had 3 orders.

Expenditure comparisons H1 FY 2025 vs H1 2026



Source: 251231 AnteoTech Ltd-Annual Report-excel cost graphs.xlsx

Sales Revenue History and H1 FY 2026 Summary




* Including US\$180,000 (A\$275,955) income received 5 days post period end

Number of Samples under evaluation is increasing



Sales pipeline growth and conversion across AnteoBind™ NXT, Anteo X®, Anteo S™ is our focus



Source: 20260225 Samples sent to Customers.xlsx

ABT Operational Highlights, H1 FY 2026, to date.



Progression of SiMRAX JDA with Black Diamond Structures (USA)

Early market test sample dispatch NEXT WEEK/Early March, to six target companies (combined **Anteo X™ cross linker with BDS's proprietary carbon nanotube formulation technology**).

Collaboration with Wyon (Switzerland)

Wyon Ultranode 70 testing continuing well. 10x scale-up of anode production achieved. Integration into Wyon battery cells in progress.

South Korea market entry - Kangshin

Distributor appointed and strong demand received for **Anteo S™** samples (our new cross linking separator product). Austrade assisting to connect to large corporates.

Ultranode™ X milestone met

Achieved **1,020 cycles at 80% capacity retention for the Company's 70% silicon anode, Ultranode™ X**, achieving market-leading capabilities. Strategic partnership sought.

Ultranode™ 95 for the Drone market progressed

Two (2) non-exclusive Ultranode™ 95 JDAs under negotiation with battery manufacturers that supply or intend to supply drones to the US defence sector and other end users.

US market product entry progressed

Distributor/agent options being progressed along with securing of large scale product import regulatory approvals.

LS Operational Highlights, H1 FY 2026, to date.



Continued relationship with Serum Institute of India and India focus

Sales order received, with payment received 5/1/2026. US\$185,000 (~AU\$275,750)¹
Interest in new applications of AnteoBind – particularly NXT™ for particle and plate-based formats across CLIA and ELISA. Attended BioAsia in India February 2026.

Re-engagement with large global life sciences companies

The first phase of a joint CLIA (chemiluminescent immunoassay) product development program incorporating AnteoBind™ NXT is under final stages of negotiation with a large global life sciences company.

New Japanese customers

New customers in Japan. Distributor engagement underway.

Expansion of sales pipeline

16 samples currently under evaluation.

Growth of customer reach and engagement

Comparative Evaluation of AnteoBind™ NXT and Tosyl-Activated Magnetic Particles in Chemiluminescent Immunoassays (CLIA) “White Paper”

Ongoing engagement with emerging diagnostic platforms

Vidcare, Fastsense, MOBIUS and others. New technology approvals present additional challenges but bring significant benefits in terms of integration into multi-test platforms.

1 = <https://www.rba.gov.au/exchange-rates-overview.html> As at 4.00 pm, 24 December 2025 was 0.6709 AU/US
2 March 2026 ©AnteoTech Limited

Business Overview



- AnteoTech Ltd (ASX: ADO) is a **chemical and materials company** with global sales with an expanding potential customer network and customer base.
- The Company is in the **commercialisation stage** of growth across both its **Advanced Battery Technologies (ABT)** and **Life Sciences (LS)** business units.
- AnteoTech's core expertise lies in **surface modification**, using its platform chemical technology which “**cross links**” at a **molecular level**, highly selectively, robustly and reproducibly.

Strategy FY 2026

Existing markets where opportunities will continue to be pursued

New opportunities to be targeted and pursued

Strategy

India



- Drive targeted sales growth through existing network facilitated by **expansion of our commercialisation pipeline.**
- Securing of strategic partnerships based on mutually beneficial, profit repatriation model basis.

USA



- Expansion of our customer base.
- Attract a **strategic partner**

South Korea & Japan



- Expand our customer base/sales.
- Attract a **strategic partners**

Europe



- Expand existing customer base.
- Attract a **strategic partners**

Life Sciences

- Further expand through the **Serum Institute of India relationship** and secure **additional similar customers.**
- Expand pipeline working with **Austrade & Trade & Investment Queensland (TIQ).**

- Target the Point-of-Care **Diagnostics, Particle and Plate markets.**

- Grow market presence through our **distributor.**
- Expand sales pipeline with support from **Austrade and TIQ.**

- Re-engage with **global Life Sciences companies across Particle and Plate markets.**

Advanced Battery Technologies

- **Target E-Mobility, Wearables and battery manufacturers and suppliers.**
- Focus on **Joint Venture and Product Development** opportunities.

- Target **Defence and Security** markets, including Unmanned Aerial Systems (UAS).
- Progress **Carbon Nanotube** joint product development.

- Work through **distributors** to grow market access.
- Expand the pipeline with support from **Austrade and TIQ.**

- Progress evaluation and commercial discussions with **WYON** and other battery supply chain participants.

Leading Cross-linking Technology Products for Electrodes and Ceramic Separator Coatings



ANTEO STM

Cross-linker for Ceramic Coated Separators (CCS)



ANTEO X[®]

Cross-linker for Silicon Anodes



SiMRAX

Anteo X + SWCNT Combination Product for Silicon Anodes

Safer and Thinner Separators

- Reinforces ceramic coating, reducing potential thermal runaway and fires.
- The global separator market ~\$14B in 2024, is projected to be ~\$25B by 2030; with a CAGR of 28%

Improved Performance

- Improved cycle life by more than 35% ¹
- Reduced anode expansion by up to 40% ²

Improved Cost Efficiency

- Reduction in CNT content by 50% ¹
- Reduction in binder content by more than 2wt% ³

All-in-one solution for high Si anodes

- The world's only additive combining high quality carbon nanotube products with unique crosslinking agents
- World's most efficient binder strengthening agent, a single product, improving performance, minimizing cost and simplifying processes

Leading in High Silicon Anode Technology



ULTRANODE™

Application	Automotive & eVTOLs	3C Markets and Micro-mobility	UAS, Drones and Defence
Ultranode technology	Ultranode® X	Ultranode® 70	Ultranode® 95
Cycle life	High (>1,000 @ 80%)	Medium (>500 @ 80%)	Medium (>200 @ 80%)
Coating capacities	Medium (700-1,100 mAh/g)	Medium (700-1,100 mAh/g)	High (1,800-2,400 mAh/g)
Supply Chain Options	Korea, China, US	Korea, China, US	Korea, China, US
Commercially scaled-up	✓	✓	✓
Engagement pathway	1. Technology partnership 2. Joint Development Agreements 3. Licensing	1. Ultranode samples 2. Ultranode + Cathode sample packs	Ultranode samples and Ultranode + Cathode sample packs


Fully accessing silicon's potential in next generation batteries AnteoTech

Silicon stores close to 10 x more Li^+ by weight and 3 x more Li^+ by volume

AnteoTech's **Ultranode™ technology** allows silicon to be used at its full potential



Vs



^{12}C - Graphite
371 mAh/g

^{28}Si - Silicon
3,579 mAh/g

Not all silicon active materials is the same!

Active material type	Specific active material capacity
Elemental micro Silicon (Si)	3,579 mAh/g *
Si/C (silane)	1,850 mAh/g ^
SiOx-Li	1,500 mAh/g

* Theoretical maximum


^ Subject to supplier

Ultranode[®] 95 delivers Superior Wh/kg for superior flight time

Unit stack (single layer cell) – Graphite/NMC811 Cell vs. Ultranode 95/NMC811 Cell

Considers: 1 anode, 1 cathode, 1 separator, Cu/Al current collectors and electrolyte

272 Wh/kg*
“Active Stack”




+40% in Wh/kg



380Wh/kg*
“Active Stack”

Δ = Thinner cell stack
results in larger Wh/L



2-3
times
Thinner

* = Specific energy values do not consider packaging, tabbing etc.

Numbers are internally calculated, based on data generated over the lifetime Ultranode™ 95 development program. Numbers stated are valid for specific anode and cathode combination. They are subject to change based on final cell design and electrode specifications.


ABT Partnerships continue to develop



SiMRAX NEW PRODUCT JDA




- JDA with BDS
- Combines AnteoTech's Anteo X with BDS's SWCNTs dispersion technology into an advanced product
- Step change in silicon anode performance delivering improved:
 - Mechanical stability
 - Battery life
 - Electrochemical performance



Ultranode 70 Scale-up/Evaluation




- Swiss medical device battery manufacturer
- 10x scale-up achieved in working with Wyon
- Integration into Wyon battery cells in progress



Opportunity pipeline ABT February 2026



ersonal use only



Note: Sales Pipeline encompasses: -Anteo X®, Anteo S™ and Ultranode™ technology. It does not include SiMRAX at this time.

The AnteoBind™ Life Sciences product suite




1. Multiplex Activation kit

- **Sales to the Serum Institute of India** for use in their Luminex in-house vaccine quality control tests.
 - **Three out of every four children worldwide receive at least one of Serum Institute vaccine** during their life lifetime.



2. AnteoBind™ Biosensor

- Supporting the development of **next-generation** immunodiagnostic tests.
- **Compatible with a range of test detection formats**, including optical and electrical sensors. Below has **AnteoBind™ NXT** inside.



C-reactive protein (CRP) serves as a vital biomarker for the real-time monitoring of inflammation, infections, and cardiovascular diseases, a sensitive and selective electrochemical immunosensor is developed for the noninvasive detection of CRP on a thin film – AnteoBind NXT™ has been used to Improve sensitivity of detection.

3. AnteoBind™ NXT

- **Delivers lower cost, higher performing (more sensitive and reliable)** immunodiagnostic tests, across **lateral flow, chemiluminescence (CLIA) particles and ELISA plate** formats.



ELISA plates



CLIA

Opportunity pipeline LS February 2026

Lateral Flow San Deigo – Oct 2025
AusBio – Oct 2025
BioAsia India – Feb 2026

Sales Qualified Lead

35

Samples under negotiation:
8

Samples under evaluation or work program proposals

16



- Serum Institute India
- Contract value: US\$1.8 million
- Contract duration: '24 to '29

Note: Sales Pipeline encompasses: AnteoBind™ NXT and all related and derived products.

Looking Forward

- \$3.5 million (net of costs) Capital Raise closed 4 February 2026 (post period end).
- With cash in bank, the potential 2026 R&D rebate and contracted sales, sound basis for progress
- Targets for 2H FY26 (by 30 June 2026) with a focus on **Sales**:
 - New LS customer conversions and partnerships
 - New diagnostic product development (CLIA and ELISA)
 - New ABT customers and JDA partnerships:-
 - New Ultranode® 95 (Drones) JDAs, Anteo X® in SiMRAX dispatched, Anteo S™ sales
- AnteoTech has grown its pipeline of sales opportunities across both business units over the half year, it continues to expand product and technology marketing to new customers with improved marketing collateral and using new market specific platforms/sales channels.
- The Company remains **well positioned to achieve significant progress moving forward.**